Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Study sponsor: Palvella Therapeutics, Inc. · PVLA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-09-19Actual
Enrollment · participants73Actual
Source updated2024-08-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.